Hematology News and Research RSS Feed - Hematology News and Research

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.
PET-CT more accurate than conventional CT in evaluating patients with follicular lymphoma

PET-CT more accurate than conventional CT in evaluating patients with follicular lymphoma

Positron emission tomography/computed tomography (PET-CT) is more accurate than conventional CT scanning in measuring response to treatment and predicting survival in patients with follicular lymphoma, and should be used routinely in clinical practice, according to new research published in The Lancet Haematology. [More]
Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $12.1 million SPORE grant from the National Cancer Institute. The five-year Specialized Programs of Research Excellence, or SPORE, grant will fund four new melanoma research projects that aim to translate fundamental laboratory discoveries into new therapeutics to treat melanoma and other skin cancers. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. [More]
Simple point-of-care testing device provides more rapid diagnosis of anemia

Simple point-of-care testing device provides more rapid diagnosis of anemia

A simple point-of-care testing device for anemia could provide more rapid diagnosis of the common blood disorder and allow inexpensive at-home self-monitoring of persons with chronic forms of the disease. [More]
SCD patients who experience discrimination are less likely to follow physician recommendations

SCD patients who experience discrimination are less likely to follow physician recommendations

Sickle Cell Disease (SCD) is the most common genetic condition detected by newborn screening in the United States - a physically devastating and painful illness affecting an estimated 100,000 individuals currently nationwide. [More]
Researchers aim to safely and quickly suppress food allergies in human

Researchers aim to safely and quickly suppress food allergies in human

In mice, the answer appears to be "yes," but making sure the same can happen in humans is a task that Fred Finkelman, MD, professor of medicine and pediatrics in the University of Cincinnati's (UC) College of Medicine and a researcher at Cincinnati Children's Hospital Medical Center, is attempting to tackle. [More]
Keytruda drug gets FDA approval for treatment of advanced melanoma

Keytruda drug gets FDA approval for treatment of advanced melanoma

The U.S. Food and Drug Administration today approved a new immunotherapy drug to treat advanced melanoma, signaling a paradigm shift in the way the deadly skin cancer is treated. [More]
Organizations across U.S. participating in Go Gold for Childhood Cancer Awareness campaign

Organizations across U.S. participating in Go Gold for Childhood Cancer Awareness campaign

Organizations in Atlanta – and across the country – are participating in the Go Gold for Childhood Cancer Awareness campaign this September. Coordinating this effort is the Aflac Cancer Center of Children's Healthcare of Atlanta along with the Stop Childhood Cancer Alliance that was created to be the driving force in increasing awareness of childhood cancer and enhancing support for the young people fighting this disease, as well as the clinicians and researchers helping them. [More]
MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a randomized Phase II clinical trial of its lead investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). [More]
Wake Forest Baptist Medical Center receives NCORP grant to conduct cancer clinical trials

Wake Forest Baptist Medical Center receives NCORP grant to conduct cancer clinical trials

Wake Forest Baptist Medical Center has received an $18 million, five-year grant from the National Cancer Institute's Community Oncology Research Program to design and conduct community-based, multi-center screening, prevention and control cancer clinical trials. [More]
BloodCenter's Erythroid Chimerism test available to monitor transplanted SCD patients

BloodCenter's Erythroid Chimerism test available to monitor transplanted SCD patients

BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of an innovative Erythroid Chimerism test to monitor erythroid lineage chimerism in patients with sickle cell disease (SCD) following allogeneic bone marrow transplantation. [More]
HICCC receives $18 million grant from the National Cancer Institute

HICCC receives $18 million grant from the National Cancer Institute

Outstanding basic research, a growing focus on translating discoveries into treatments, and a dedication to patient care have earned the Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center Support Grant from the National Cancer Institute (NCI). [More]
Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. [More]
Experimental drug shows promise as viable treatment for anemia of inflammation

Experimental drug shows promise as viable treatment for anemia of inflammation

An experimental drug designed to help regulate the blood's iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment published online today in Blood, the Journal of the American Society of Hematology. [More]
Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia (CML). [More]
Targeting club cells may help shorten duration of flu symptoms

Targeting club cells may help shorten duration of flu symptoms

A specialized subset of lung cells can shake flu infection, yet they remain stamped with an inflammatory gene signature that wreaks havoc in the lung, according to a study published in The Journal of Experimental Medicine. [More]
Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

The fungal infection invasive aspergillosis (IA) can be life threatening, especially in patients whose immune systems are weakened by chemotherapy or immunosuppressive drugs. Despite the critical need for early detection, IA remains difficult to diagnose. [More]
Researchers gain rare insight into pregnancy-associated breast cancer

Researchers gain rare insight into pregnancy-associated breast cancer

During pregnancy, certain hormones trigger specialized mammary stem cells to create milk-producing cells essential to lactation. [More]
Feist-Weiller, Caris Life Sciences partner to offer breakthrough technology to cancer patients

Feist-Weiller, Caris Life Sciences partner to offer breakthrough technology to cancer patients

Doctors at the LSU Health Shreveport Feist-Weiller Cancer Center will now have access to innovative, precision-medicine technology that determines the unique biological characteristics of each individual patient's cancer tumor. [More]